Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Genomic determinants of response to blinatumomab

Yaqi Zhao • 11 Apr 2022
AACR 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

In this video, Yaqi Zhao, MSc, St. Jude Children’s Research Hospital, Memphis, TN, discusses the genomic determinants of response to blinatumomab in patients with B-cell acute lymphoblastic leukemia (B-ALL). Ms Zhao explains a study which found that blinatumomab resistance is associated with deleterious mutations in CD22, and that patients with the high-risk (Ph)-like subtype have a superior response rate to blinatumomab. Ms Zhao also briefly discusses a recent study analyzing bone marrow samples from 4 patients with B-ALL which found that resistance to blinatumomab is associated with T cell exhaustion. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

More from Yaqi Zhao

0:47
Novel targeted antibodies for R/R B-ALL
Yaqi Zhao • 11 Apr 2022
1:59
Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
Yaqi Zhao • 11 Apr 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals